Global Asthma Network (GAN). The Global Asthma Report. http://www.globalasthmareport.org (2018).

Chen, C. et al. Prevalence, economic burden, and neurophenotype of asthma. Explor. Res. Hypothesis Med. 8, 359–365 (2023).

Article  Google Scholar 

Wang, Z. et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir. Res. 24, 169 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Global Initiative for Asthma. Global strategy for asthma management and prevention. http://ginasthma.org/ (2023).

Price, D., Fletcher, M. & van der Molen, T. Asthma control and management in 8000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 24, 14009 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Maspero, J. F. et al. Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin America. World Allergy Organ J. 6, 19 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Price, D. et al. Time for a new language for asthma control: results from REALISE Asia. J. Asthma Allergy 8, 93–103 (2015).

PubMed  PubMed Central  Google Scholar 

World Health Organization. Asthma. https://www.who.int/news-room/fact-sheets/detail/asthma (2024).

Levy, M. L. The national review of asthma deaths: what did we learn and what needs to change? Breathe 11, 14–24 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Haughney, J. et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir. Med. 102, 1681–1693 (2008).

Article  PubMed  Google Scholar 

Bateman, E. D. et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur. Respir. J. 59, 2101402 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Global Initiative for Asthma. Global strategy for asthma management and prevention. http://ginasthma.org/ (2018).

Reddel, H. K. et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur. Respir. J. 53, 1901046 (2019).

Article  PubMed  Google Scholar 

Bloom, C. I. et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK Study as part of the SABINA Global Program. Adv. Ther. 37, 4190–4208 (2020).

Article  CAS  PubMed  Google Scholar 

FitzGerald, J. M., Tavakoli, H., Lynd, L. D., Al Efraij, K. & Sadatsafavi, M. The impact of inappropriate use of short acting beta agonists in asthma. Respir. Med. 131, 135–140 (2017).

Article  PubMed  Google Scholar 

Nwaru, B. I. et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur. Respir. J. 55, 1901872 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stanford, R. H., Shah, M. B., D’Souza, A. O., Dhamane, A. D. & Schatz, M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann. Allergy Asthma Immunol. 109, 403–407 (2012).

Article  CAS  PubMed  Google Scholar 

Global Initiative for Asthma. Global strategy for asthma management and prevention. http://ginasthma.org/ (2019).

O’Byrne, P. M., Jenkins, C. & Bateman, E. D. The paradoxes of asthma management: time for a new approach? Eur. Respir. J. 50, 1701103 (2017).

Article  PubMed  Google Scholar 

Blakeston, S., Harper, G. & Zabala Mancebo, J. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. J. Asthma 58, 1094–1101 (2021).

Article  CAS  PubMed  Google Scholar 

Loh, Z. C. et al. Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: a systematic review. PLoS ONE 18, e0283876 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Partridge, M. R., van der Molen, T., Myrseth, S. E. & Busse, W. W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 6, 13 (2006).

Article  PubMed  PubMed Central  Google Scholar 

Tattersfield, A. E. et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am. J. Respir. Crit. Care Med. 160, 594–599 (1999).

Article  CAS  PubMed  Google Scholar 

Stolbrink, M. et al. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. Lancet Glob. Health 10, e1423–e1442 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farouk, H. et al. Over-the-counter (OTC) short-acting β2-agonist (SABA) purchase and asthma outcomes in SABINA III. Eur. Respir. J. 60, 3434 (2022).

Google Scholar 

Loh, Z. C. et al. Over-the-counter use of short-acting beta-2 agonists: a systematic review. J. Pharm. Policy Pr. 16, 119 (2023).

Article  Google Scholar 

Diaz, D. V. et al. Short-acting β2-agonist prescription patterns in patients with asthma in the Philippines: results from SABINA III. Acta Med. Philipp. 57, 12–24 (2023).

PubMed  PubMed Central  Google Scholar 

Avdeev, S. et al. SABA overuse in Russia—burden and possible causes: an analysis of the Russian population in the SABINA III (SABA use IN Asthma) study. J. Asthma Allergy 15, 371–379 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakaya, J., Mecha, J. & Beekman, M. Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study. BMC Prim. Care 24, 141 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith, C. et al. Over-prescription of short-acting β2-agonists for asthma in South Africa: results from the SABINA III study. Afr. J. Thorac. Crit. Care Med. 28, https://doi.org/10.7196/AJTCCM.2022.v28i4.220 (2022).

Price, D. et al. The association between short-acting β2-agonist over-prescription, and patient-reported acquisition and use on asthma control and exacerbations: data from Australia. Adv. Ther. 41, 1262–1283 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vialle-Valentin, C. E., Serumaga, B., Wagner, A. K. & Ross-Degnan, D. Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries. Health Policy Plan 30, 1044–1052 (2015).

Article  PubMed  Google Scholar 

Gibson, P. et al. Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ 306, 1514–1518 (1993).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henry, D. A., Sutherland, D. & Francis, L. The use of non-prescription salbutamol inhalers by asthmatic patients in the Hunter Valley, New South Wales. Newcastle Retail Pharmacy Research Group. Med. J. Aust. 150, 445–449 (1989).

Article  CAS  PubMed  Google Scholar 

Reddel, H. K., Ampon, R. D., Sawyer, S. M. & Peters, M. J. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open 7, e016688 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Azzi, E. A. et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey. BMJ Open 9, e028995 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Amirav, I. & Newhouse, M. T. Asthma and COVID-19: in defense of evidence-based SABA. J. Asthma Allergy 13, 505–508 (2020).